New stably transfected bioluminescent cells expressing FLAG epitope-tagged estrogen receptors to study their chromatin recruitment.

Publisher: BioMed Central Country of Publication: England NLM ID: 101088663 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6750 (Electronic) Linking ISSN: 14726750 NLM ISO Abbreviation: BMC Biotechnol Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2001-

Cell Line* ; Transfection*; Chromatin/*metabolism ; Estrogen Receptor alpha/*metabolism ; Estrogen Receptor beta/*metabolism; Chromatin Immunoprecipitation ; Epitopes/metabolism ; Estrogen Receptor alpha/genetics ; Estrogen Receptor beta/genetics ; Gene Expression Regulation ; HeLa Cells ; Humans ; Luciferases/genetics ; Luciferases/metabolism ; Transcriptional Activation

Background: Biological actions of estrogens are mediated by the two specific estrogen receptors ERalpha and ERbeta. However, due to the absence of adequate cellular models, their respective transcriptional activities are still poorly understood. For instance, the evaluation of such differing properties on the transcription of responsive genes using ChIP experiments was hindered by the deficiency of cells exhibiting the same genotypic background and properties but expressing only one of the ERs. We describe here the generation of such cells, using an estrogen receptor negative HELN cell line that was derived from HeLa cells stably transfected with an ERE-driven luciferase plasmid. These HELN-Falpha and HELN-Fbeta cell lines stably express either the alpha or beta (full length) estrogen receptor tagged with the FLAG epitope. The use of antibodies directed against the FLAG epitope allowed a direct comparative evaluation of the respective actions of both ERs using ChIP.
Results: HELN-Falpha and HELN-Fbeta cell lines were found to express comparable levels of their corresponding tagged receptors with a Kd for estradiol binding of 0.03 and 0.27 nM respectively. The presence of a stably transfected ERE-driven luciferase plasmid in these cells allowed the direct evaluation of the transcriptional activity of both tagged receptors, using natural or synthetic estrogens. FLAG-ERalpha and FLAG-ERbeta were found to exhibit similar transcriptional activity, as indicated by a kinetic evaluation of the transcriptional activation of the luciferase gene during 10 hrs of treatment with estradiol. The validity of these model cells was further confirmed by the predictable transcriptional regulations measured upon treatments with ERalpha or ERbeta specific ligands. The similar immunoprecipitation efficiency of both tagged receptors by an anti-FLAG antibody allowed the assessment of their kinetic recruitment on the synthetic luciferase promoter (containing an estrogen response element) by ChIP assays during 8 hours. A biphasic curve was obtained for both FLAG-ERalpha and FLAG-ERbeta, with a peak occurring either at 2 hr or at 1 hr, respectively, and a second one following 4 hr of E2 stimulation in both cases. In MCF-7 cells, the recruitment of ERalpha also exhibited a biphasic behaviour; with the second peak however not so important than in the HeLa cell lines.
Conclusion: In HELN derived cell lines, no fundamental differences between kinetics were observed during 8 hours for FLAG-ERalpha and FLAG-ERbeta, as well as for polymerase II recruitment. However, the relative importance of recruitment between 1 hr and 4 hr was found to be different in HeLa cell line expressing exogenous tagged ERalpha and in MCF-7 cell line expressing endogenous ER.

Annu Rev Physiol. 2001;63:165-92. (PMID: 11181953)
J Biol Chem. 2002 Jul 5;277(27):24353-60. (PMID: 11986316)
J Mol Endocrinol. 2005 Apr;34(2):553-66. (PMID: 15821116)
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2604-9. (PMID: 18272478)
Cancer Res. 1998 Jan 15;58(2):210-4. (PMID: 9443393)
Nature. 2008 Mar 6;452(7183):112-5. (PMID: 18322535)
Nature. 2008 Mar 6;452(7183):45-50. (PMID: 18322525)
Int J Biochem Cell Biol. 2009 Jan;41(1):214-24. (PMID: 18930837)
EMBO Rep. 2006 Feb;7(2):161-7. (PMID: 16452926)
Cell Signal. 2008 Jul;20(7):1368-74. (PMID: 18450422)
Mol Interv. 2003 Aug;3(5):281-92. (PMID: 14993442)
Cancer Res. 2007 Jun 1;67(11):5513-21. (PMID: 17545634)
J Biol Chem. 2008 Mar 14;283(11):6752-63. (PMID: 18174157)
Nucleic Acids Res. 1998 Aug 1;26(15):3505-12. (PMID: 9671811)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15578-83. (PMID: 12438700)
J Med Chem. 2001 Nov 22;44(24):4230-51. (PMID: 11708925)
Mol Cell. 2003 Mar;11(3):695-707. (PMID: 12667452)
FEBS Lett. 2002 Jul 31;524(1-3):1-5. (PMID: 12135731)
Mol Cell. 2008 May 9;30(3):336-47. (PMID: 18471979)
Nucl Recept Signal. 2008 Feb 01;6:e003. (PMID: 18301783)
J Cell Biochem. 2007 Aug 1;101(5):1125-47. (PMID: 17520659)
Genomics. 1993 Jul;17(1):263-5. (PMID: 8406468)
Breast Cancer Res Treat. 2008 May;109(2):241-50. (PMID: 17638070)
Endocr Rev. 2005 May;26(3):465-78. (PMID: 15857973)
Mol Endocrinol. 2006 Feb;20(2):291-301. (PMID: 16179380)
Cell. 2003 Dec 12;115(6):751-63. (PMID: 14675539)
J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65. (PMID: 9398750)
Mol Cell. 2000 Jun;5(6):939-48. (PMID: 10911988)
Biochem Biophys Res Commun. 1998 Jun 9;247(1):75-8. (PMID: 9636657)
Sci Total Environ. 1999 Aug 15;233(1-3):47-56. (PMID: 10492897)
Endocrinology. 2003 Aug;144(8):3541-6. (PMID: 12865336)
Biochem Pharmacol. 2006 May 14;71(10):1459-69. (PMID: 16554039)
J Biol Chem. 2002 Apr 26;277(17):14359-62. (PMID: 11893728)
Cancer Res. 2007 Apr 15;67(8):3955-62. (PMID: 17440111)
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30. (PMID: 8650195)
Mol Endocrinol. 2006 Mar;20(3):534-43. (PMID: 16293641)
Mol Endocrinol. 2007 Jan;21(1):1-13. (PMID: 16556737)
J Med Chem. 2000 Dec 28;43(26):4934-47. (PMID: 11150164)
Cell. 2000 Dec 8;103(6):843-52. (PMID: 11136970)

0 (Chromatin)
0 (Epitopes)
0 (Estrogen Receptor alpha)
0 (Estrogen Receptor beta)
EC 1.13.12.- (Luciferases)

Date Created: 20090910 Date Completed: 20091102 Latest Revision: 20231105

20231105

PMC2749030

10.1186/1472-6750-9-77

19737428